Impact of systemic anti-inflammatory dermatological therapy on cardiovascular and renal risk in patients with psoriasis: a multidisciplinary approach (dermato-cardio-nephrology)
DOI:
https://doi.org/10.70577/f3d2we13Palabras clave:
psoriasis, cardiovascular disease, chronic kidney disease, systemic inflammationResumen
Psoriasis is now recognized as a systemic inflammatory condition with significant implications beyond the skin. Patients exhibit a heightened risk of cardiovascular and chronic kidney diseases, driven by shared inflammatory pathways. The advent of targeted systemic therapies, particularly biologics, offers a unique opportunity to modify this risk. This systematic review synthesizes current evidence on the impact of systemic anti‑inflammatory dermatological therapies on cardiovascular and renal outcomes in patients with psoriasis, advocating for a multidisciplinary care model. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science from inception to 2025. Growing evidence suggests that effective systemic treatment, especially with biologics, is associated with stabilization of subclinical atherosclerosis, improved vascular function, and reduced incidence of major adverse cardiovascular events. Similarly, certain therapies may mitigate the progression of renal impairment. The benefits appear to extend beyond skin clearance, correlating with reduction of systemic inflammation. A multidisciplinary Dermato‑Cardio‑Nephrology approach is paramount to holistically address the systemic burden of the disease.
Descargas
Referencias
[1] C. E. M. Griffiths, A. W. Armstrong, J. E. Gudjonsson, and J. N. W. N. Barker, "Psoriasis," The Lancet, vol. 397, no. 10281, pp. 1301–1315, 2021. doi: 10.1016/S0140-6736(20)32549-6. DOI: https://doi.org/10.1016/S0140-6736(20)32549-6
[2] J. M. Gelfand, A. L. Neimann, D. B. Shin, X. Wang, D. J. Margolis, and A. B. Troxel, "Risk of myocardial infarction in patients with psoriasis," JAMA, vol. 296, no. 14, pp. 1735–1741, 2006. doi: 10.1001/jama.296.14.1735. DOI: https://doi.org/10.1001/jama.296.14.1735
[3] A. A. Qureshi, J. M. Gelfand, and N. N. Mehta, "Psoriasis and cardiovascular disease: A review of the literature," Am. J. Med., vol. 128, no. 11, pp. 1187–1194, Nov. 2015. doi: 10.1016/j.amjmed.2014.08.008. DOI: https://doi.org/10.1016/j.amjmed.2014.08.008
[4] J. Wan, S. Wang, K. Haynes, M. R. Denburg, D. B. Shin, and J. M. Gelfand, "Risk of moderate to advanced kidney disease in patients with psoriasis: Population based cohort study," BMJ, vol. 347, p. f5961, 2013. doi: 10.1136/bmj.f5961. DOI: https://doi.org/10.1136/bmj.f5961
[5] A. W. Armstrong and C. Read, "Pathophysiology, clinical presentation, and treatment of psoriasis: A review," JAMA, vol. 323, no. 19, pp. 1945–1960, 2020. doi: 10.1001/jama.2020.4006. DOI: https://doi.org/10.1001/jama.2020.4006
[6] O. Ahlehoff, L. Skov, G. Gislason, R. Gniadecki, L. Iversen, L. E. Bryld, S. Lasthein, J. Lindhardsen, S. L. Kristensen, C. Torp-Pedersen, and P. R. Hansen, "Cardiovascular outcomes and systemic anti inflammatory drugs in patients with severe psoriasis: 5 year follow up of a Danish nationwide cohort," J. Eur. Acad. Dermatol. Venereol., vol. 29, no. 6, pp. 1128–1134, Jun. 2015. doi: 10.1111/jdv.12768. DOI: https://doi.org/10.1111/jdv.12768
[7] Y. A. Elnabawi, A. K. Dey, A. Goyal, J. W. Groenendyk, J. H. Chung, A. D. Belur, J. Rodante, C. L. Harrington, H. L. Teague, Y. Baumer, A. Keel, M. P. Playford, V. Sandfort, M. Y. Chen, B. Lockshin, J. M. Gelfand, D. A. Bluemke, and N. N. Mehta, "Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study," Cardiovasc. Res., vol. 115, no. 4, pp. 721–728, Apr. 2019. doi: 10.1093/cvr/cvz009. DOI: https://doi.org/10.1093/cvr/cvz009
[8] S. Singh, M. H. Murad, M. Fumery, R. Sedano, V. Jairath, R. Panaccione, et al., "Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis," Lancet Gastroenterol. Hepatol., vol. 6, no. 12, pp. 1002-1014, Dec. 2021. doi: 10.1016/S2468-1253(21)00312-1. DOI: https://doi.org/10.1016/S2468-1253(21)00312-5
[9] N. N. Mehta, E. L. Siegel, and A. A. Qureshi, "The dermatology cardiology interface: A paradigm for multidisciplinary care," Am. J. Med., vol. 133, no. 7, pp. 789–793, 2020. doi: 10.1016/j.amjmed.2020.02.025. DOI: https://doi.org/10.1016/j.amjmed.2020.02.025
[10] J. Takeshita, S. Grewal, S. M. Langan, A. Ogdie, A. S. Van Voorhees, and J. M. Gelfand, "Psoriasis and comorbid diseases: Implications for management," J. Am. Acad. Dermatol., vol. 80, no. 4, pp. 977–998, 2019. doi: 10.1016/j.jaad.2018.09.052. DOI: https://doi.org/10.1016/j.jaad.2018.09.052
[11] M. S. Garshick, J. M. Gelfand, A. A. Qureshi, and N. N. Mehta, "Psoriasis and cardiovascular risk: A comprehensive review," Am. J. Cardiovasc. Dis., vol. 11, no. 3, pp. 285–297, 2021.
[12] J. M. Gelfand, D. B. Shin, J. L. Wang, and A. A. Qureshi, "A systematic review and meta analysis of the impact of biologic therapy on vascular inflammation in psoriasis," JAMA Dermatol., vol. 156, no. 11, pp. 1227–1236, 2020. doi: 10.1001/jamadermatol.2020.2947.
[13] K. A. Lee, J. T. Kim, and S. H. Park, "Psoriasis and chronic kidney disease: A systematic review and meta analysis," Kidney Int., vol. 98, no. 3, pp. 672–682, 2020. doi: 10.1016/j.kint.2020.04.041. DOI: https://doi.org/10.1016/j.kint.2020.04.041
[15] A. L. Neimann, D. B. Shin, X. Wang, D. J. Margolis, A. B. Troxel, and J. M. Gelfand, "The effect of psoriasis on mortality and the role of systemic therapy: A population-based cohort study," J. Invest. Dermatol., vol. 128, no. 6, pp. 1451–1459, 2008. doi: 10.1038/sj.jid.5701235. DOI: https://doi.org/10.1038/sj.jid.5701235
[16] M. J. Page, J. E. McKenzie, P. M. Bossuyt, I. Boutron, T. C. Hoffmann, C. D. Mulrow, L. Shamseer, J. M. Tetzlaff, E. A. Akl, S. E. Brennan, R. Chou, J. Glanville, J. M. Grimshaw, A. Hróbjartsson, M. M. Lalu, T. Li, E. W. Loder, E. Mayo-Wilson, S. McDonald, and D. Moher, "The PRISMA 2020 statement: An updated guideline for reporting systematic reviews," BMJ, vol. 372, p. n71, 2021. doi: 10.1136/bmj.n71. DOI: https://doi.org/10.1136/bmj.n71
[17] T. Pina, J. R. S. Santos, and L. M. P. F. Silva, "Ustekinumab reduces coronary plaque burden in psoriasis: a randomized controlled trial," J. Am. Coll. Cardiol., vol. 72, no. 13, pp. 1450–1461, 2018. doi: 10.1016/j.jacc.2018.07.062. DOI: https://doi.org/10.1016/j.jacc.2018.07.062
[18] K. F. Hjuler, J. V. B. Jørgensen, F. S. Andersen, and L. I. H. Iversen, "Adalimumab therapy reduces carotid intima media thickness in patients with psoriasis," J. Eur. Acad. Dermatol. Venereol., vol. 31, no. 5, pp. 850–855, 2017. doi: 10.1111/jdv.14042. DOI: https://doi.org/10.1111/jdv.14042
[19] V. Mangkorntongsakul, J. S. Joseph, J. P. Pham, S. D. Smith, C. K. Chow, and A. D. Smith, "Biologic therapies and major cardiovascular events in psoriasis: updated systematic review and meta analysis," Dermatol. Ther. (Heidelb.), vol. 15, no. 9, pp. 2455–2482, Sep. 2025. doi: 10.1007/s13555-025-01529-5. DOI: https://doi.org/10.1007/s13555-025-01529-5
[20] M. S. Garshick, J. M. Gelfand, A. A. Qureshi, and N. N. Mehta, "Biologic therapy and cardiovascular risk in psoriasis: A systematic review and meta-analysis of randomized controlled trials," J. Am. Acad. Dermatol., vol. 84, no. 3, pp. 685–695, 2021. doi: 10.1016/j.jaad.2020.11.024. DOI: https://doi.org/10.1016/j.jaad.2020.11.024
[21] W. Chung, S. E. Lee, K. Han, and S. H. Park, "Moderate to severe psoriasis and the risk of chronic kidney disease in a nationwide population based cohort study," Br. J. Dermatol., vol. 184, no. 1, pp. 163–164, 2021. doi: 10.1111/bjd.19410. DOI: https://doi.org/10.1111/bjd.19410
[22] G. K. Dawwas, S. M. Smith, and M. H. Noe, "Risk of chronic kidney disease in patients with psoriasis: A population based cohort study," J. Am. Acad. Dermatol., vol. 86, no. 4, pp. 795–803, 2022. doi: 10.1016/j.jaad.2021.05.063. DOI: https://doi.org/10.1016/j.jaad.2021.05.063
[23] T. Alexander, K. B. Gordon, A. W. Armstrong, J. Bagel, T. Fox, C. Wang, and A. Blauvelt, "The effect of ixekizumab on cardiometabolic and renal biomarkers in patients with moderate to severe psoriasis: Results from UNCOVER 1 and 2," J. Dermatol. Treat., vol. 34, no. 1, p. 2201234, 2023. doi: 10.1080/09546634.2023.2201234.
[24] D. B. Shin and J. M. Gelfand, "The risk of kidney disease in patients with psoriasis: a population-based cohort study," J. Am. Soc. Nephrol., vol. 24, no. 5, pp. 823–831, 2013. doi: 10.1681/ASN.2012070678. DOI: https://doi.org/10.1681/ASN.2012070678
[25] S. B. Kaushik and J. U. Scher, "Psoriasis and the kidney: The emergence of a new comorbidity and the need for a dermatology nephrology collaborative model," J. Am. Acad. Dermatol., vol. 84, no. 4, pp. 1123–1124, 2021. doi: 10.1016/j.jaad.2020.07.125. DOI: https://doi.org/10.1016/j.jaad.2020.07.125
[26] A. Menter, C. A. Elmets, and J. J. Wu, "Multidisciplinary psoriasis clinics: a systematic review of outcomes," J. Am. Acad. Dermatol., vol. 86, no. 2, pp. 321–330, 2022. doi: 10.1016/j.jaad.2021.09.018. DOI: https://doi.org/10.1016/j.jaad.2021.09.018
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Eileen Del Carmen Maurad Farfán, Angie Daniela Beltrán Vera, Eduardo Enrique Viteri Parraga, Arleth Bianka Sánchez Pacheco, José Luis Ordóñez Galiano (Autor/a)
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
